MDT-AP-3175
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36
- os_event
- true
- age_years
- 9.7
- sex
- M
- new_clusters
- C1
- umap1_2d
- 4.15371297
- umap2_2d
- 0.179982689
- umap1_3d
- 0.418495289
- umap2_3d
- -2.039468591
- umap3_3d
- -0.03822686
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.370
- KRAS_SIGNALING_DN+0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- SPERMATOGENESIS+0.290
- ANGIOGENESIS+0.220
- APICAL_SURFACE+0.170
- MYOGENESIS+0.150
- KRAS_SIGNALING_UP+0.120
- ESTROGEN_RESPONSE_LATE+0.080
- TNFA_SIGNALING_VIA_NFKB+0.080
Top 10 suppressed
- PROTEIN_SECRETION-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.390
- MYC_TARGETS_V1-0.380
- OXIDATIVE_PHOSPHORYLATION-0.380
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- COMPLEMENT-0.330
- IL6_JAK_STAT3_SIGNALING-0.330
- ANDROGEN_RESPONSE-0.280
- MITOTIC_SPINDLE-0.280
- HEDGEHOG_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1276 | Med | Medulloblastoma | 0.855 |
| 2 | TCGA-DK-A3X1-01A-12R-A22U-07 | — | — | 0.849 |
| 3 | SRR6013476 | — | cohortSQ1 | 0.834 |
| 4 | SRR1516070 | — | — | 0.825 |
| 5 | MNG472 | — | — | 0.824 |
| 6 | SRR1430972 | GTEX | — | 0.821 |
| 7 | MNG225 | — | — | 0.820 |
| 8 | SRR26320080 | — | — | 0.819 |
| 9 | SRR1353285 | GTEX | — | 0.817 |
| 10 | 82982 | EPN | Supratentorial EPN | 0.814 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.080 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.060 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |